American Association for Cancer Research Co-Hosts Conference on Molecular Targets and Cancer Therapeutics

Newswise — BOSTON, MASS. — The American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC) will host their annual International Conference on Molecular Targets and Cancer Therapeutics from Oct. 19-23, 2013, at the Hynes Convention Center in Boston, Mass.

The meeting, focusing on cancer drug development, draws nearly 3,000 attendees and gathers academics, scientists, and representatives from the pharmaceutical industry to discuss the effects new discoveries in cancer therapeutics and target selection have in molecular biology.

The online program can be found at www.aacr.org/targets2013program.

A press kit containing press releases and highlighted abstracts will be available Oct. 14.

Press conferences will be held in Room 202 of the Hynes Convention Center:

Press conferences will include:

• Sunday, Oct. 20, 10 a.m. “Emerging Therapeutics,” including research on investigational drugs AZD9291 and PF-06463922, which have the potential to overcome drug resistance in some lung cancers.• Monday, Oct. 21, 9 a.m. “Overcoming Resistance and Hard-to-Treat Cancers,” including research on a new antibody-drug conjugate MLN0264 for pancreatic cancer and a new nanopharmaceutical CRLX101 for cancers resistant to antiangiogenic drugs. • Tuesday, October 22, 9 a.m. “Guiding Treatment for BRAF- and BRCA-related Cancers,” including updated data on the clinical benefit of the PARP inhibitor BMN 673 and a new diagnostic platform to rapidly identify BRAF mutations.

Reporters who cannot attend in person should dial in using the following numbers:

• U.S./Canada (toll-free): 800-446-2782 • International (toll): 847-413-3235

Registration will be available to members of the media who provide press credentials. For more information or to register for the meeting, please contact Lauren Riley at [email protected] or 215-446-7155 or Jeremy Moore at [email protected] or 215-446-7109.

###